Cargando…

Inadequate Dosage May Lead to the Recurrence of Postoperative Pulmonary Hypertension in Patients With Congenital Heart Disease

Background: Pulmonary arterial hypertension (PAH) associated with congenital heart disease (PAH-CHD) occurs predominantly among patients with uncorrected congenital heart disease (CHD). It is an intractable problem to control PAH continuously and stably after an operation. Methods: 1) OPLS-DA combin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Xinmei, Li, Te
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8117148/ https://www.ncbi.nlm.nih.gov/pubmed/33995082 http://dx.doi.org/10.3389/fphar.2021.660405

Ejemplares similares

Combined Methods (Formal Adjusted Indirect Comparison, Meta-Analysis and Principal Component Analysis) Comparisons of the Safety and Efficacy of Ambrisentan, Bosentan, and Sildenafil in the Patients With Pulmonary Arterial Hypertension
por: Li, Xinmei, et al.
Publicado: (2020)

Intravenous sildenafil for postoperative pulmonary hypertension in children with congenital heart disease
por: Fraisse, Alain, et al.
Publicado: (2010)

Evaluating the role of serum uric acid in the risk stratification and therapeutic response of patients with pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD)
por: Luo, Jun, et al.
Publicado: (2023)

Pulmonary hypertension in congenital heart disease
por: Pascall, Emma, et al.
Publicado: (2018)

Cost-effectiveness of maintenance niraparib with an individualized starting dosage in patients with platinum-sensitive recurrent ovarian cancer in China
por: Shi, Yin, et al.
Publicado: (2023)

Pulmonary vasodilators can lead to various complications in pulmonary “arterial” hypertension associated with congenital heart disease
por: Chida-Nagai, Ayako, et al.
Publicado: (2020)

Predicted Vancomycin Dosage Requirement in Patients With Hematological Malignancies and Dosage Dynamic Adjustment
por: Song, Xiangqing, et al.
Publicado: (2022)

Inadequate gastric preparation and its associated factors for magnetically controlled capsule endoscopy
por: Kong, Qing-Zhou, et al.
Publicado: (2023)

Role of heparanase in pulmonary hypertension
por: Wang, Lin-Jun, et al.
Publicado: (2023)

Unpredictable Nanoparticle Retention in Commonly Used Plastic Syringes Introduces Dosage Uncertainties That May Compromise the Accuracy of Nanomedicine and Nanotoxicology Studies
por: Holzwarth, Uwe, et al.
Publicado: (2019)

Efficacy evaluation of pulmonary hypertension therapy in patients with portal pulmonary hypertension: A systematic review and meta-analysis
por: Zhang, Ruihua, et al.
Publicado: (2022)

Segmental Pulmonary Hypertension in Children with Congenital Heart Disease
por: Das, Bibhuti B., et al.
Publicado: (2020)

Editorial: Pulmonary hypertension associated with congenital heart disease
por: He, Siyi, et al.
Publicado: (2023)

Population pharmacokinetics of voriconazole and initial dosage optimization in patients with talaromycosis
por: Jiang, Zhiwen, et al.
Publicado: (2022)

Atorvastatin May Attenuate Recurrence of Chronic Subdural Hematoma
por: Liu, Hua, et al.
Publicado: (2016)

Statins for the Treatment of Pulmonary Hypertension in Patients with Chronic Obstructive Pulmonary Disease
por: Chen, Chung-Yu, et al.
Publicado: (2021)

Initial Dosage Recommendation for Sirolimus in Children With Tuberous Sclerosis Complex
por: Wang, Dong-Dong, et al.
Publicado: (2020)

MicroRNA-204 as an Indicator of Severity of Pulmonary Hypertension in Children with Congenital Heart Disease Complicated with Pulmonary Hypertension
por: Li, Xu, et al.
Publicado: (2019)

Therapeutic Strategies in Pulmonary Hypertension
por: Fuso, Leonello, et al.
Publicado: (2011)

Role of connexins in human congenital heart disease: the chicken and egg problem
por: Salameh, Aida, et al.
Publicado: (2013)

AI Models to Assist Vancomycin Dosage Titration
por: Wang, Zhiyu, et al.
Publicado: (2022)

Therapy for Pulmonary Arterial Hypertension: Glance on Nitric Oxide Pathway
por: Tettey, Abraham, et al.
Publicado: (2021)

Population Pharmacokinetics of Polymyxin B and Dosage Optimization in Renal Transplant Patients
por: Li, Ying, et al.
Publicado: (2021)

Inadequate Sedation Leads to Unexpected Postoperative Wound Evisceration during a Bedside Endoscopy
por: Kim, Im-kyung, et al.
Publicado: (2018)

Anesthetic management of pediatric with congenital heart disease with pulmonary hypertension
por: Singh, Dipika, et al.
Publicado: (2014)

Riociguat for pulmonary arterial hypertension associated with congenital heart disease
por: Rosenkranz, Stephan, et al.
Publicado: (2015)

Echocardiography for the Assessment of Pulmonary Hypertension and Congenital Heart Disease in the Young
por: Meinel, Katharina, et al.
Publicado: (2020)

Evaluation and Management of Pulmonary Arterial Hypertension in Congenital Heart Disease
por: Arshad, Hassaan B., et al.
Publicado: (2021)

Population Pharmacokinetics and Dosage Optimization of Teicoplanin in Children With Different Renal Functions
por: Gao, Liuliu, et al.
Publicado: (2020)

Population Pharmacokinetics of Vancomycin in Chinese ICU Neonates: Initial Dosage Recommendations
por: Li, Zhi-ling, et al.
Publicado: (2018)

Pulmonary Hypertension in Adult Congenital Heart Disease in Asia: A Distinctive Feature of Complex Congenital Heart Disease
por: Chiu, Shuenn‐Nan, et al.
Publicado: (2022)

Pain may be inevitable; inadequate management is not
por: Skrobik, Yoanna
Publicado: (2008)

Initial sirolimus dosage recommendations for pediatric patients with PIK3CD mutation-related immunodeficiency disease
por: Chen, Xiao, et al.
Publicado: (2022)

Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Pulmonary arterial hypertension associated with congenital heart disease
por: Lopes, Antonio, et al.
Publicado: (2014)

Better Outcomes in Pulmonary Arterial Hypertension After Repair of Congenital Heart Disease, Compared With Idiopathic Pulmonary Arterial Hypertension
por: Xu, Zhuoyuan, et al.
Publicado: (2021)

Effect of iloprost on biomarkers in patients with congenital heart disease‐pulmonary arterial hypertension
por: Li, Xiao‐ye, et al.
Publicado: (2017)

Predictors of operability in children with severe pulmonary hypertension associated with congenital heart disease
por: Xi, Shi-Bing, et al.
Publicado: (2019)

Pulmonary arterial hypertension populations of special interest: portopulmonary hypertension and pulmonary arterial hypertension associated with congenital heart disease
por: Savale, Laurent, et al.
Publicado: (2019)

The Efficacy and Safety of Pulmonary Vasodilators in Pediatric Pulmonary Hypertension (PH): A Systematic Review and Meta-analysis
por: Shu, Tingting, et al.
Publicado: (2021)

Medicinal Plants and Phytochemicals for the Treatment of Pulmonary Hypertension
por: Jasemi, Seyed Vahid, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4u69c6hpcls4j505dquclie65b